IDEAYA Biosciences (IDYA) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Legend Biotech (LEGN) over the past year, gaining 34.4% versus a loss of 41.9%. Over five years, IDYA leads with a +55.9% price change compared with -64.0% for LEGN. Legend Biotech is the larger company by market cap ($3.70 billion vs $3.48 billion), about 1.1 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +64.0%).
Legend Biotech converts more of its revenue into profit, with a net margin of -28.8% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | LEGN |
|---|---|---|
| Share price | $36.08 | $19.04 |
| Market cap | $3.48B | $3.70B |
| 1-day change | +0.04% | +1.76% |
| YTD return | +4.31% | -13.94% |
| 1-year return | +34.35% | -41.91% |
| 5-year return | +55.90% | -63.96% |
| Forward P/E | — | 18.13 |
| EPS (TTM) | $-1.94 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $1.03B |
| Revenue growth (YoY) | +3024.43% | +64.04% |
| Net income (latest FY) | $-113.70M | $-296.80M |
| Gross margin | — | 61.41% |
| Operating margin | -72.84% | -13.27% |
| Net margin | -51.99% | -28.85% |
| 52-week high | $42.68 | $37.50 |
| 52-week low | $26.05 | $16.24 |
| Distance from 52-week high | -15.48% | -49.23% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +46.22% | +144.22% |
| Average volume | 779.15K | 2.37M |
| Shares outstanding | 96.49M | 194.49M |
| Employees | 145 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed LEGN by 76.3 percentage points over the past year.
- Legend Biotech is more profitable, keeping -28.8 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +64.04%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
IDYA vs LEGN FAQ
Which is bigger, IDEAYA Biosciences or Legend Biotech?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.70B compared with $3.48B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or LEGN?
IDYA returned +34.35% over the past 12 months, compared with -41.91% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.